Netherlands halts use of AstraZeneca vaccine amid blood clotting concerns

The Dutch authorities are halting the use of the AstraZeneca vaccine against the coronavirus amid concerns over recent blood clotting incidents

AstraZeneca
Photo: Reuters
ANI Europe
1 min read Last Updated : Mar 15 2021 | 7:08 AM IST

The Dutch authorities are halting the use of the AstraZeneca vaccine against the coronavirus amid concerns over recent blood clotting incidents.

"On the basis of new information, the Dutch Medicines Evaluation Board (CBG) has advised, as a precautionary measure and pending further investigation, to pause the administration of the AstraZeneca corona vaccine," the Dutch government announced on Sunday.

According to the statement, the AstraZeneca vaccine will not be used in the next two weeks, until March 28.

Earlier on Sunday, Ireland suspended the use of the AstraZeneca vaccine as new information emerged on blood clotting incidents in Norway.

On Saturday, the Norwegian Medicines Agency said that more cases of blood clotting had been found in adults who received AstraZeneca vaccine shots.

Earlier this week, several European countries, including Denmark, Iceland and Norway, halted the rollout of the AstraZeneca vaccine after Austria said it was investigating the death of a vaccinated woman from multiple thromboses.

The UK-Swedish pharmaceutical giant AstraZeneca said on Sunday that it had found no evidence of increased risk of blood clots from its COVID-19 vaccine after conducting a review of safety data of over 17 million inoculated people across the European Union and the United Kingdom.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus VaccineAstraZeneca

First Published: Mar 15 2021 | 7:04 AM IST

Next Story